Global Myasthenia Gravis Treatment Market, By Radiation Type (Proton Radiation, Electron Radiation, Photon Radiation, Carbon-Lon Radiation), Application (Prostate Cancer, Lung Cancer, Breast Cancer, Brain Cancer, Gynaecological Cancers, Gastrointestinal Cancers, Other Cancers), End User (Hospitals, Independent Radiotherapy Centers, Other) – Industry Trends and Forecast to 2031.
Myasthenia Gravis Treatment Market Analysis and Size
The market for myasthenia gravis treatment is being driven by a number of factors, including the rising incidence of cancer and the advancements in radiotherapy technology, as well as an increase in the global elderly population. Furthermore, increased awareness about the benefits of IMRT among patients, healthcare professionals, and referring physicians has led to greater acceptance and adoption of this treatment modality. Collaboration between technology companies, healthcare institutions, and research organizations has led to the development of more innovative IMRT solutions, which are further driving market growth. Many countries are investing in healthcare infrastructure, including the establishment of cancer treatment centers and radiation therapy facilities, which have boosted the accessibility of the myasthenia gravis treatment market.
Furthermore, ongoing advancements in radiotherapy technology, including improvements in imaging, treatment planning software, and delivery systems, have enhanced the precision and effectiveness of IMRT. These advancements are attracting both patients and healthcare providers. These technologies will further accelerate the growth of the market in the forecast period of 2024-2031. However, the acquisition and installation of IMRT equipment can be expensive. This cost can pose a significant barrier to healthcare facilities, particularly in resource-constrained regions, limiting the availability of IMRT services which is expected to act as a challenge for the market in the forecast period of 2024-2031.
Data Bridge Market Research analyzes that the myasthenia gravis treatment market, which was USD 2423.69 million in 2023, is likely to reach USD 4867.77 million by 2031 and is expected to undergo a CAGR of 9.1% during the forecast period. “Hospitals” dominate the end-user segment of the market due to the convenience of consolidated medical services under one roof, streamlining patient care, and making IMRT an attractive treatment option there. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Radiation Type (Proton Radiation, Electron Radiation, Photon Radiation, Carbon-Lon Radiation), Application (Prostate Cancer, Lung Cancer, Breast Cancer, Brain Cancer, Gynaecological Cancers, Gastrointestinal Cancers, Other Cancers), End User (Hospitals, Independent Radiotherapy Centers, Other)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, Spain, Turkey, U.K., Netherlands, Russia, Switzerland, Belgium, Hungary, Italy, Rest of Europe, China, India, Japan, Australia, South Korea, Malaysia, Singapore, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Mettler-Toledo (U.S.), Varian Medical Systems (U.S.), Elekta AB (Sweden), Accuray (U.S.), Siemens Healthineers (Germany), IBA Dosimetry (Belgium), Sun Nuclear Corporation (U.S.), ViewRay (U.S.), RaySearch Laboratories (Sweden), Mevion Medical Systems (U.S.), Hitachi Healthcare (Japan), Prowess Inc. (a subsidiary of Altair) (U.S.), Brainlab (Germany), Koninklijke Philips N.V. ( Netherlands)
|
|
Market Opportunities
|
|
Market Definition
Myasthenia gravis treatment (IMRT) is an advanced radiotherapy technique used in the treatment of various forms of cancer. IMRT is designed to deliver highly focused and precise doses of radiation to cancer cells while minimizing exposure to healthy surrounding tissues.
Global Myasthenia Gravis Treatment Market Dynamics
Drivers
- Increasing cancer incidence
The rising incidence of cancer globally is a significant driver for the IMRT market. As the number of cancer cases continues to grow, the demand for effective and targeted radiation therapy methods like IMRT is also increasing. Thus, the market for myasthenia gravis treatment is being driven by a number of factors, including the adoption of IMRT which is growing in emerging markets due to increased healthcare spending and the expansion of healthcare infrastructure.
- Rising geriatric population
The rising cancer incidence and population aging are two of the most important factors driving market growth. Globocan predicts that the number of new cancer cases will rise by 47% from 2020 to 28.4 million over the next two decades. Furthermore, the elderly are more vulnerable to cancer, and life expectancy in developing countries has surpassed 80 years. These are the certain factors which help the market to grow.
- Favourable reimbursement policies
In many developed countries, there are favourable reimbursement policies for radiotherapy treatments, including IMRT. This financial support encourages patients to opt for advanced and effective treatments such as IMRT.
Moreover, increased awareness about the benefits of IMRT among patients, healthcare professionals, and referring physicians has led to greater acceptance and adoption of this treatment modality. This further accelerate the market growth.
Opportunity
- Increasing advancements in radiation therapy technologies
Ongoing advancements in radiotherapy technology, including improvements in imaging, treatment planning software, and delivery systems, have enhanced the precision and effectiveness of IMRT. These advancements are attracting both patients and healthcare providers. Image-Guided Radiotherapy (IGRT) involves the use of advanced imaging techniques, such as cone-beam CT scans and MRI, to precisely locate and track tumors in real time during treatment. This allows for adjustments in radiation delivery based on the tumor's position, minimizing damage to surrounding healthy tissues. This precise targeting minimizes radiation exposure to healthy tissues, making it especially useful in complex tumor shapes and locations, which can, in turn, will create lucrative market growth opportunities.
Moreover, collaboration between technology companies, healthcare institutions, and research organizations has led to the development of more innovative IMRT solutions, which will also work in the favour of the market.
Restraints/Challenge
- High installation cost of equipment
On the other hand, the acquisition and installation of IMRT equipment can be expensive. This cost can pose a significant barrier to healthcare facilities, particularly in resource-constrained regions, limiting the availability of IMRT services which is expected to obstruct market growth. Moreover, lack of highly skilled radiation oncologists, medical physicists, and radiation therapists that can be simply is projected to challenge the market in the forecast period of 2024-2031.
This myasthenia gravis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the myasthenia gravis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In October 2020, Serialized Product Intelligence is a new cloud service developed by TraceLink that uses serialisation data to give actionable intelligence and operational excellence
Global Myasthenia Gravis Treatment Market Scope
The myasthenia gravis treatment market is segmented on the basis of radiation type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Radiation Type
- Proton Radiation
- Electron Radiation
- Photon Radiation
- Carbon-Ion Radiation
Application
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Brain Cancer
- Gynaecological Cancers
- Gastrointestinal Cancers
- Other Cancers
End-User
- Hospitals
- Independent Radiotherapy Centers
- Other
Global Myasthenia Gravis Treatment Market Regional Analysis/Insights
The myasthenia gravis treatment market is analyzed and market size insights and trends are provided by country, radiation type, application and end-user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Brazil, Argentina, rest of South America, Germany, France, Italy, U.K., Belgium, Spain, Russia, Turkey, Netherlands, Switzerland, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, U.A.E., Saudi Arabia, Egypt, South Africa, Israel, and rest of Middle East and Africa.
North America dominates the myasthenia gravis treatment market due to rise in global geriatric population and government expenditures on healthcare in the region.
Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the growing aging demographic in Asia-Pacific countries underscores the need for effective cancer treatment with minimal adverse effects, aligning with IMRT's precision-driven attributes.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Myasthenia Gravis Treatment Market Share Analysis
The myasthenia gravis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to myasthenia gravis treatment market.
Some of the major players operating in the myasthenia gravis treatment market are:
- Mettler-Toledo (U.S.)
- Varian Medical Systems (U.S.)
- Elekta AB (Sweden)
- Accuray (U.S.)
- Siemens Healthineers (Germany)
- IBA Dosimetry (Belgium)
- Sun Nuclear Corporation (U.S.)
- ViewRay (U.S.)
- RaySearch Laboratories (Sweden)
- Mevion Medical Systems (U.S.)
- Hitachi Healthcare (Japan)
- Prowess Inc. (a subsidiary of Altair) (U.S.)
- Brainlab (Germany)
- Koninklijke Philips N.V. (Netherlands)
SKU-